GE Healthcare says its Serena Bright is now available in the United States following U.S. FDA 510(k) clearance. Serena Bright is the industry’s first contrast-enhanced guided biopsy solution allowing clinicians to conduct breast biopsy exams with contrast guidance using the same mammography equipment as that used for screening or diagnostic mammography.
Typically, for lesions found with contrastenhanced mammography and not seen on ultrasound, clinicians will use other imaging guidance, such as MRI, for biopsy procedures. Following an abnormal mammogram, it can take several weeks to get an MRI biopsy.
As the backlog of cancer screenings caused by Covid-19 persists, delays in diagnosis will likely lead to presentation at more advanced stages and poorer clinical outcomes, with one study pointing to a potential increase of 33,890 excessive cancer deaths in the U.S. alone.
Serena Bright may help decrease these delays, allowing follow-up biopsy procedures to be done in a matter of days, rather than several weeks for MRI biopsy. When compared to MRI-biopsy guided therapy, the potential benefits of Contrast Enhanced Spectral Mammography (CESM) biopsy include shortened procedure time and improved overall patient experience.
Key to this technology’s application is GE Healthcare’s SenoBright HD CESM, a diagnostic breast exam with iodine-based contrast that provides high sensitivity for more accurate breast cancer diagnosis.
By highlighting areas of unusual blood flow to localize lesions that need to be biopsied, CESM biopsy – Serena Bright – provides excellent image quality to help improve clinical confidence.
For more information, visit: www.gehealthcare.com/products/ mammography/serena-bright
Supplier: GE Healthcare